Status:
COMPLETED
Study of Investigational Drug in Osteoporosis (MK-0217-908)
Lead Sponsor:
Organon and Co
Conditions:
Postmenopausal Osteoporosis
Eligibility:
FEMALE
50+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of an investigational drug in postmenopausal women with osteoporosis. The primary hypothesis of this study is that in postmenopausal wo...
Eligibility Criteria
Inclusion
- postmenopausal for at least 3 years, with osteoporosis at any of the following sites: \[BMD \> 2.0 standard deviations below young normal mean bone mass for the hip trochanter, PA lumbar spine (L1 to L4), total hip, or femoral neck based on the normative database provided by each individual manufacturer\].
- willing to take study-supplied calcium and vitamin D supplement (or equivalent) and to discontinue any non-study calcium supplements for run-in period and the duration of the study.
Exclusion
- pregnant or lactating, or of childbearing potential.
- participated in another therapeutic trial with an investigational compound within 30 days of randomization.
- history of hypersensitivity to any component of ibandronate tablets or has hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
- an abnormality of the esophagus which delays esophageal emptying such as stricture or achalasia.
- unable to stand or sit upright for at least 60 minutes once a month.
- current use of illicit drugs, or history of drug or alcohol abuse within the past five years.
- has any of the following: hypocalcemia; any severe malabsorption syndrome; moderate or severe hypertension which is uncontrolled; new onset angina or myocardial infarction within six months of entry into the study; evidence for impaired renal function; organ transplantation; or other significant end organ diseases (genitourinary, cardiovascular, endocrine, hepatic, psychiatric, renal, hematologic, or pulmonary).
- history of or evidence of metabolic bone disease (other than postmenopausal bone loss).
- clinical fracture in the past year.
- is receiving or has received treatment prior to randomization which might influence bone turnover.
- is receiving or expected to receive during the course of the study any medication (other than study medication) which might alter bone or calcium metabolism, including Vitamin A in excess of 10,000 IU per day or Vitamin D in excess of 5000 IU per day, calcitonin, phenytoin, heparin, or lithium.
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2005
Estimated Enrollment :
203 Patients enrolled
Trial Details
Trial ID
NCT00092053
Start Date
December 1 2004
End Date
July 1 2005
Last Update
February 2 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.